---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-173796"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T18:08:24.109104+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics recasts FY2022 financials after reverse split; reports net loss of $37.7M

## Summary
- Annual meeting elected directors Heyman and Kintz; ratified Deloitte & Touche as auditor for FY2023.
- Recasted FY2022 net loss of $37.7M ($12.05 per share) vs $24.7M in FY2021.
- R&D expense rose 51% to $31.0M; G&A expense increased to $7.8M.
- Cash and equivalents totaled $75.5M at Dec 31, 2022, down from $110.0M a year earlier.
- Company expects current cash to fund operations for at least 12 months from March 2023.

## SEC filing metadata
- accession: 0001193125-23-173796
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312523173796/0001193125-23-173796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312523173796/d514661d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-173796
- JSON: https://secwatch.observer/filing/0001193125-23-173796.json
- Plain text: https://secwatch.observer/filing/0001193125-23-173796.txt

## Key facts
- Shareholder Votes
  Enliven Therapeutics, Inc. shareholders approved Election of two Class III Directors at the 2023-06-23 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-23
  source text: Name of Director For Withheld Broker Non-Votes Richard Heyman, Ph.D. 30,518,067 385,508 1,641,388 Samuel Kintz, M.B.A. 30,900,278 3,297 1,641,388
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523173796/0001193125-23-173796-index.htm
- Shareholder Votes
  Enliven Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-23 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-23
  source text: For Against Abstain 32,543,338 1,460 165
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523173796/0001193125-23-173796-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.